The economic value of personalized medicine tests: what we know and what we need to know

Abstract

Purpose There is uncertainty about when personalized medicine tests provide economic value. We assessed evidence on the economic value of personalized medicine tests and gaps in the evidence base. Methods We created a unique evidence base by linking data on published cost–utility analyses from the Tufts Cost-Effectiveness Analysis Registry with data measuring test characteristics and reflecting where value analyses may be most needed: (i) tests currently available or in advanced development, (ii) tests for drugs with Food and Drug Administration labels with genetic information, (iii) tests with demonstrated or likely clinical utility, (iv) tests for conditions with high mortality, and (v) tests for conditions with high expenditures. Results We identified 59 cost–utility analyses studies that examined personalized medicine tests (1998–2011). A majority (72%) of the cost/quality-adjusted life year ratios indicate that testing provides better health although at higher cost, with almost half of the ratios falling below $50,000 per quality-adjusted life year gained. One-fifth of the results indicate that tests may save money. Conclusion Many personalized medicine tests have been found to be relatively cost-effective, although fewer have been found to be cost saving, and many available or emerging medicine tests have not been evaluated. More evidence on value will be needed to inform decision making and assessment of genomic priorities.

Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability

“…The findings of this research can be used as input in the discussion regarding the societal, individual, and monetary value of next-generation sequencing. 12 A recent study assessed comprehensive costs of the traditional diagnostic pathway in a different group of patients, with complex pediatric neurological disorders. 13 However, a clear determination of the diagnostic yield when actually performing WES compared with traditional diagnostic procedures and costs was not made.…”

Personalized Medicine as an Updated Model of National Health-Care System. Part 2. Towards Public and Private Partnerships

“…В качестве примера одного из трен-дов в этом отношении можно привести технологиче-ские разработки, ориентированные на использование комбинаторных пакетов инструментов, отслежива-ющих динамику эндомикробиоты с одной стороны и эпигеномного контроля -с другой. Также отмечен (4) и растущий спрос на системы мониторинга -вве-дение сенсоров в практику позволяет анализировать состояние организма и принимать лечащему врачу решения в режиме реального времени [3].…”

“…РОССИЙСКИЙ ВЕСТНИК ПЕРИНАТОЛОГИИ И ПЕДИАТРИИ, 2017; 62: (4) ROSSIYSKIY VESTNIK PERINATOLOGII I PEDIATRII, 2017; 62: (4) АКТУАЛЬНОСТЬ ПРОБЛЕМЫ К ак уже говорилось в предыдущей статье, карди-нальный перелом во взглядах на роль и место медицины в структуре охраны здоровья произошел на рубеже 80-90-х гг. прошлого столетия.…”

“…The perspectives of personalized pediatrics as a global instrument for restructuring the entire healthcare system are considered in detail. (4) вокруг активно разрабатываемого направления, получившего название персонализированной меди-цины. Именно эта модель, основанная на раннем (доклиническом) выявлении признаков заболевания и последующих превентивно-профилактических ме-роприятиях, способна реально стабилизировать по-казатели заболеваемости и снизить инвалидность, существенно уменьшив при этом традиционно вы-сокие расходы на лечение уже заболевших людей (включая детей).…”

From systems biology to P4 medicine: applications in respiratory medicine

“…Finally, because of the high cost of overcoming these challenges, there is a significant risk that individuals in developing countries will not benefit from this health revolution [121], unless guided by the appropriate political efforts from the international community and an informed public opinion [122][123][124]. Even within the richest nations, equitable access to P4 medicine is not guaranteed, and low-income individuals may not be able to afford the unsubsidised cost of omics data integration, diagnostic and clinical care [125,126].…”